CYR212 / Cyrus Biotech - LARVOL DELTA

Degradation of IgG autoantibodies associated with platelet disorders by a half-life extended IgG protease (ASH 2025) - "Treatment options for ITP include IVIG, rituximab, or plasmapheresis toreduce anti-platelet autoantibodies (Mititelu A, et al...Wild type (WT) IdeS (drug name imlifidase) has enabled platelettransfusion in a patient with severe alloimmune platelet refractoriness (Qamar A, et al...Pharmacokinetics (PK) in C57BL/6 mice, humanized FcRn mice, and hFcRn/Albumin-KO micesupported modeling of long human PK with an elimination half-life of 9.6 days.Overall, the data show CYR212 achieves rapid and deep depletion of IgG, with low immunogenicity foreffective repeat doses. The profile is well suited for rapidly addressing antibody-mediated hematologicalemergencies and long-term maintenance therapy."

Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Rheumatology • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia (Businesswire) - "Cyrus Biotechnology...has been selected as its clinical development candidate for chronic IgG-driven autoimmune disease. CYR212 was selected based on promising recent preclinical data from evaluations of pharmacokinetics, pharmacodynamics and immunogenicity in animal models. Preclinical studies in rabbits confirmed a significant extension of half-life and pharmacodynamic IgG-reducing activity compared to the wild type (WT) Streptococcus pyogenes IdeS protease, from which CYR212 has been developed....Cyrus plans to take CYR212 into clinical studies in indications where the anti-FcRn class have so far not proven sufficiently potent for clinical approval (ITP), or where lower IgG levels achievable by CYR212 are likely to lead to better efficacy (gMG)."

Preclinical • Immune Thrombocytopenic Purpura • Myasthenia Gravis